Medical Oncology

, 30:615 | Cite as

Outcomes of locally advanced breast cancer patients with ≥10 positive axillary lymph nodes

  • Emre Koca
  • Taha Y. Kuzan
  • Omer Dizdar
  • Taner Babacan
  • Ilyas Sahin
  • Erhan Ararat
  • Kadri Altundag
Original Paper

Abstract

Breast cancers with 10 or more positive lymph nodes at the time of diagnosis are staged as pathological N3a (pN3a) and they have poor prognosis. Recent studies showed five-year disease-free survival (DFS) and overall survival (OS) rates of N3a disease as 43–66 and 58–81 %, respectively. We herein present outcomes of our patients with stage pN3a breast cancer. Among 2,578 patients diagnosed with invasive breast carcinoma at Hacettepe University Hospital between 2002 and 2012, 218 patients (8.4 %) had pN3a disease and were included and analyzed retrospectively in this study. Patients with internal mammary, infraclavicular, and supraclavicular node metastasis or distant metastasis at initial diagnosis were excluded. Demographic features, tumor characteristics, treatment regimens, and patient outcomes in terms of DFS and OS were analyzed. Lymph node ratio was defined as the ratio of positive to total removed lymph nodes. The median age was 49. Most common histological subtype was ductal carcinoma (82.1 %). About 82.6 % of patients had stage T2/T3 cancers and 47.7 % (104) had grade III cancers. Estrogen and progesterone receptors were positive in 133 (61 %) and 121 (55.5 %) patients, respectively. HER2 status was known for 213 patients and was positive in 87 (39.9 %) patients. A total of 27 (12.6 %) patients had triple-negative tumors. Lymphovascular invasion, extracapsular extension, and perineural invasion were present in 106 (48.6 %), 105 (48.2 %), 20 (9.2 %) cases, respectively. A total of 18 patients (8.3 %) received neoadjuvant and 200 patients (91.7 %) received adjuvant chemotherapy, mostly with anthracycline- (95 %) and taxane (60 %)-containing regimens. A total of 210 patients (96.3 %) received radiotherapy. Median follow-up was 39.5 months. A total of 96 patients relapsed on follow-up and 64 patients died. Nineteen of the relapses were locoregional and 77 were distant relapses. The 5-year DFS rate was 46.2 % and the OS rate was 69.8 %. In multivariate Cox regression analysis, grade III disease (HR 1.899, 95 % CI 1.196–3.017, P = 0.007), perineural invasion (HR 2.519, 95 % CI 1.341–4.731, P = 0.004), and lymph node ratio (≥0.9 vs. <0.9) (HR 2.290, 95 % CI 1.368–3.835, P = 0.002) were significantly associated with DFS, and grade III disease (HR 2.679, 95 % CI 1.500–4.782, P = 0.001) and lymph node ratio (≥0.9 vs. <0.9) (HR 2.182, 95 % CI 1.211–3.932, P = 0.009) were significantly associated with OS. Patients with pN3a disease in our cohort have comparable survival rates with other reports in the literature. Within this high risk group of patients, those with grade III disease, perineural invasion, and lymph node ratio ≥0.9 seem to confer poorer prognosis.

Keywords

Breast cancer Stage pN3a Treatment Outcome 

Notes

Conflict of interest

There is no conflict of interest for all authors.

References

  1. 1.
    Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401.PubMedCrossRefGoogle Scholar
  2. 2.
    Glass AG, Lacey JV Jr, Carreon JD, et al. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Newman LA. Epidemiology of locally advanced breast cancer. Semin Radiat Oncol. 2009;19:195–203.PubMedCrossRefGoogle Scholar
  4. 4.
    Cianfrocca M, Goldstein LC. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. SurgClin North Am. 2003;83:803–19.CrossRefGoogle Scholar
  6. 6.
    Basaran G, Devrim C, Caglar HB, Gulluoglu B, Kaya H, Seber S, Korkmaz T, Telli F, Kocak M, Dane F, Yumuk FP, Turhal SN. Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years? Med Oncol. 2011;28:726–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee JS, Kim SI, Choi SY, Park HS, Lee JS, Park S, Koo J, Park BW, Lee KS. Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. Int J Clin Oncol. 2011;16:473–81.PubMedCrossRefGoogle Scholar
  8. 8.
    van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.PubMedCrossRefGoogle Scholar
  9. 9.
    Montero AJ, Rouzier R, Lluch A, et al. The natural history of breast carcinoma in patients with [or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer. 2005;104:229–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Duraker N, Caynak ZC, Bati B. Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma? Ann SurgOncol. 2008;15:430–7.Google Scholar
  11. 11.
    Buzdar AU, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-b containing adjuvant therapy. Cancer. 1992;69(2):448–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Walker MS, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M. German breast cancer study group. Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer. 2001;37:1123–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Ito M, Moriya T, Ishida T, et al. Significance of pathological evaluation for lymphatic vessel invasion in invasive breastcancer. Breast Cancer. 2007;14:381–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240:306–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol. 2006;24:2910–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Schiffman SC, McMasters KM, Scoggins CR, Martin RC, Chagpar AB. Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. J Am Coll Surg. 2011;213:45–52.PubMedCrossRefGoogle Scholar
  18. 18.
    van der Wal BC, Butzelaar RM, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002;28:481–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhu C, Wu XZ. Proposal of new classification for stage III breast cancer on the number and ratio of metastatic lymph nodes. J Surg Oncol. 2012;106:696–702.PubMedCrossRefGoogle Scholar
  20. 20.
    Chagpar AB, Camp RL, Rimm DL. Lymph node ratio should be considered for incorporation into staging for breast cancer. Ann Surg Oncol. 2011;18:3143–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Vinh-Hung V, Verkooijen HM, Fioretta G, Neyroud-Caspar I, Rapiti E, Vlastos G, Deglise C, Usel M, Lutz JM, Bouchardy C. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Geara FB, Nasr E, Tucker SL, Charafeddine M, Dabaja B, Eid T, Abbas J, Salem Z, Shamseddine A, Issa P, El Saghir N. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome. Int J Radiat Oncol Biol Phys. 2007;68:364–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Petrelli F, Borgonovo K, Barni S. The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. Eur J Surg Oncol. 2011;37:836–47.PubMedCrossRefGoogle Scholar
  24. 24.
    Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol. 2012 Dec 23. [Epub ahead of print].Google Scholar
  25. 25.
    John BJ, Naik P, Ironside A, Davidson BR, Fusai G, Gillmore R, Watkins J, Rahman SH. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford). 2013;. doi: 10.1111/hpb.12019.Google Scholar
  26. 26.
    Qiu C, Dong W, Su B, Liu Q, Du J. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer. J Thorac Oncol. 2013;8:429–35.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Emre Koca
    • 1
  • Taha Y. Kuzan
    • 1
  • Omer Dizdar
    • 2
  • Taner Babacan
    • 1
  • Ilyas Sahin
    • 1
  • Erhan Ararat
    • 1
  • Kadri Altundag
    • 1
    • 3
  1. 1.Hacettepe University Cancer InstituteAnkaraTurkey
  2. 2.Department of Medical OncologyBaskent University HospitalAnkaraTurkey
  3. 3.Department of Medical OncologyHacettepe University Institute of OncologySihhiye, AnkaraTurkey

Personalised recommendations